September 17, 2019 by Jason Lee
The global pneumonia vaccines market was valued at $7,083 million in 2017 and is expected to reach $10,215 million by 2025, growing at a CAGR of 5% from 2018 to 2025.
Pneumonia is a lung infection that occurs in one or both the lungs caused by bacteria, viruses, or fungi; however, bacterial pneumonia is the most common form occurring in adults.
Request for Sample report @ https://www.factomarketinsights.com/sample/189
Pneumonia results in inflammation in the air sacs (known as alveoli) of the lungs, which results in filling the alveoli with fluid (pus cells), thus causing breathing problems. Pneumococcal disease is common in young children, but older adults are at greatest risk of serious pneumococcal infections and even death.
Thus, Center for Disease Control and Prevention (CDC) recommends administration of two pneumococcal vaccines, PCV13 and PPSV23. The key factors that drive the growth of the global pneumonia vaccine market include increase in prevalence of pneumonia across the globe, rise in government focus on immunization programs for pneumonia, and introduction of novel pneumococcal vaccines such as PCV10. However, longer timelines required for pneumonia vaccine production and high cost associated with the development of such vaccines restrain the market growth. Moreover, development of protein-based combination pneumococcal vaccines is expected to provide lucrative opportunities for the expansion of this market.
The global pneumonia vaccine market is segmented based on type, product, distribution channel, sector, and region. Based on type, the market is bifurcated into pneumococcal conjugate vaccine (PCV) and pneumococcal polysaccharide vaccine (PPV). Products covered in the study include Synflorix, Prevnar 13, PPSV- 23, PCV 13-PIPELINE, V114-MERCK, PCV-20-PFIZER, and PCV-10-SII. Based on distribution channel, the market is categorized into distribution partner companies, non-governmental organizations (NGO), and government authorities. Based on sector, the market is bifurcated into public and private. Based on region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Access Complete Research report with TOC @ https://www.factomarketinsights.com/report/189/pneumonia-vaccine-market-amr
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
Analysis by type helps understand the various types of pneumonia vaccines used by healthcare providers.
Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Vaccine Type
By Product Type
By distribution channel
LIST OF KEY PLAYERS PROFILED IN THE REPORT (VACCINE PROVIDERS)
Check Discount @ https://www.factomarketinsights.com/discount/189
Facto market insights is one of the leading providers of market intelligence products and services. We offer reports on over 10+ industries and update our collection daily which helps our clients to access database of expert market insights on global industries, companies, products, and trends.
Our in-house research experts have a wealth of knowledge in their respective domains. With Facto Market Research, you always have the choice of getting customized report free of cost (upto 10%). Our support team will help you customize the report and scope as per your business needs. This ensures that you are making the right purchase decision.
150 State St.
Tel: +1 518-300-1215